The aggregate repurchase authorization program now totals $200 million, which the firm will fund with cash and cash equivalents.

The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

The purchase includes the manufacturing process of four ELISA kits, two of which are in vitro diagnostic products for specialty diagnostics and disease monitoring.

The Switzerland-based firm's MosaiQ AiPlex Connective Tissue Diseases (CTDplus) assay is used to aid the diagnosis of autoimmune diseases.

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

NEW YORK – With the launch of its first product, a rule-out test for pancreatic cysts that can help risk-stratify patients who may have pancreatic cancer, Purdue University spinout Amplified Sciences ...

The firm said that it has received approval for a test that combines the Allsheng-developed Auto-Pure 2400 liquid handling platform with Revvity's T-SPOT.TB test.

NEW YORK — ABL Diagnostics said on Wednesday that it has signed an agreement for the distribution of its infectious disease molecular assays in India with Genient Tech Private.

Geneoscopy has appointed Amit Bhalla its CFO. He will support the launch of the firm’s ColoSense RNA-based, noninvasive colorectal cancer screening test. Bhalla has more than 25 years of experience in ...